Ayuda
Ir al contenido

Dialnet


Resumen de Redacted.

Charles Seife

  • The article reports that the U.S. Food and Drug Administration is seldom accused of being too transparent regarding certain important data about the performance of drugs and pharmaceutical companies . It mentions that FDA took the highly unusual step of approving a drug, eteplirsen, which is designed to help certain patients with Duchenne muscular dystrophy (DMD), against the advice of the agency's experts. It states that FDA made its adverse-events database easier to search.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus